- Home
- ETON vs MIN Comparison
ETON vs MIN Comparison
Compare ETON & MIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- MIN
- Stock Information
- Founded
- ETON 2017
- MIN 1988
- Country
- ETON United States
- MIN United States
- Employees
- ETON N/A
- MIN N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- MIN Trusts Except Educational Religious and Charitable
- Sector
- ETON Health Care
- MIN Finance
- Exchange
- ETON Nasdaq
- MIN Nasdaq
- Market Cap
- ETON 329.8M
- MIN 306.1M
- IPO Year
- ETON 2018
- MIN N/A
- Fundamental
- Price
- ETON $13.35
- MIN $2.70
- Analyst Decision
- ETON Strong Buy
- MIN
- Analyst Count
- ETON 3
- MIN 0
- Target Price
- ETON $27.67
- MIN N/A
- AVG Volume (30 Days)
- ETON 228.8K
- MIN 331.0K
- Earning Date
- ETON 03-18-2025
- MIN 01-01-0001
- Dividend Yield
- ETON N/A
- MIN 7.31%
- EPS Growth
- ETON N/A
- MIN N/A
- EPS
- ETON N/A
- MIN 0.08
- Revenue
- ETON $39,011,000.00
- MIN N/A
- Revenue This Year
- ETON $107.69
- MIN N/A
- Revenue Next Year
- ETON $65.50
- MIN N/A
- P/E Ratio
- ETON N/A
- MIN $33.38
- Revenue Growth
- ETON 23.29
- MIN N/A
- 52 Week Low
- ETON $3.03
- MIN $2.52
- 52 Week High
- ETON $18.41
- MIN $2.88
- Technical
- Relative Strength Index (RSI)
- ETON 39.80
- MIN 51.36
- Support Level
- ETON $12.73
- MIN $2.66
- Resistance Level
- ETON $15.10
- MIN $2.73
- Average True Range (ATR)
- ETON 0.98
- MIN 0.03
- MACD
- ETON -0.10
- MIN -0.00
- Stochastic Oscillator
- ETON 23.17
- MIN 46.67
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.